{'fraction_non_alphanumeric': 0.029874213836477988, 'fraction_numerical': 0.009433962264150943, 'mean_word_length': 5.923913043478261, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rokumigan alleviates oxaliplatin‐induced cold hypersensitivity by suppression of transient receptor potential cation channel subfamily M member 8 and subfamily A member 1

Oxaliplatin (Oxp) is a chemotherapeutic agent that is used to treat advanced or recurrent colorectal cancer. Oxp causes cold hypersensitivity in the acute therapy stage, however, by overexpression of the transient receptor potential cation channel subfamily melastatin, member 8 (TRPM8) and subfamily ankyrin, member 1 (TRPA1) ion channels, which sense low temperatures. In this study, we examined the effect of rokumigan (RG) on Oxp‐induced cold hypersensitivity.